| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Clinical Trial |
Department of Physiology, Australian Institute of Sport, P.O. Box 176, Belconnen ACT 2616, Australia. robin.parisotto@ausport.gov.au.
BACKGROUND AND OBJECTIVE: The use of recombinant human erythropoietin (r-HuEPO) to enhance athletic performance is prohibited. Existing tests cannot readily differentiate between exogenous and endogenous EPO. Therefore the aim of our study was to investigate possible indirect detection of r-HuEPO use via blood markers of altered erythropoiesis. DESIGN AND METHODS: Twenty-seven recreational athletes were assigned to three groups prior to a 25 day drug administration phase, with the following protocols: EPO+IM group (n = 10), 50 Ukg(-1) r-HuEPO at a frequency of 3wk(-1), 100 mg intramuscular (IM) iron 1wk(-1) and a sham iron tablet daily; EPO+OR group (n = 8), 50 U.kg(-1) r-HuEPO 3wk(-1), sham iron injection 1wk(-1) and 105 mg of oral elemental iron daily; placebo group (n = 9), sham r-HuEPO injections 3wk(-1), sham iron injections 1wk(-1) and sham iron tablets daily. Each group was monitored during and for 4 weeks after drug administration. RESULTS: Models incorporating combinations of the variables reticulocyte hematocrit (RetHct), serum EPO, soluble transferrin receptor, hematocrit (Hct) and % macrocytes were analyzed by logistic regression. One model (ON-model) repeatedly identified 94-100% of r-HuEPO group members during the final 2 wk of the r-HuEPO administration phase. One false positive was recorded from a possible 189. Another model (OFF-model) incorporating RetHct, EPO and Hct was applied during the wash-out phase and, during the period of 12-21 days after the last r-HuEPO injection, it repeatedly identified 67-72% of recent users with no false positives. INTERPRETATION AND CONCLUSIONS: Multiple indirect hematologic and biochemical markers used simultaneously are potentially effective for identifying current or recent users of r-HuEPO.
This article has been cited by other articles:
|
|
 |
|
  J. Mallorqui, J. Segura, C. de Bolos, R. Gutierrez-Gallegom, and J. A. Pascual Reply to: [Comment to: Recombinant erythropoietin found in seized blood bags from sportsmen. Haematologica 2008;93:313-4 Haematologica, July 1, 2008; 93(7): e56 - e56. [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Gore, W. G. Hopkins, and C. M. Burge Errors of measurement for blood volume parameters: a meta-analysis J Appl Physiol, November 1, 2005; 99(5): 1745 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P Wilkerson, J. Rittweger, N. J. A Berger, P. F Naish, and A. M Jones Influence of recombinant human erythropoietin treatment on pulmonary O2 uptake kinetics during exercise in humans J. Physiol., October 15, 2005; 568(2): 639 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Breidbach, D. H. Catlin, G. A. Green, I. Tregub, H. Truong, and J. Gorzek Detection of Recombinant Human Erythropoietin in Urine by Isoelectric Focusing Clin. Chem., June 1, 2003; 49(6): 901 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Brugnara A Hematologic "Gold Standard" for Iron-deficient States? Clin. Chem., July 1, 2002; 48(7): 981 - 982. [Full Text] [PDF]
|
|
|
|
 |
|
 Y O Schumacher, A Schmid, D Konig, and A Berg Effects of exercise on soluble transferrin receptor and other variables of the iron status Br. J. Sports Med., June 1, 2002; 36(3): 195 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Skibeli, G. Nissen-Lie, and P. Torjesen Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin Blood, December 15, 2001; 98(13): 3626 - 3634. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
